Table 1. Sample summary information.
Demographics and sample background in life stages corresponding to later sample restrictions (premenopausal, 18 to 45; menopause transition or perimenopause, 46 to 54; postmenopause, 55+). Note that <10 was used for any cells with fewer than 10 individuals. Ages are binned on the basis of approximate life stages and the sample restrictions. *, 23 respondents had two doses of the vaccine but did not specify the vaccine type.
| Total (N = 39,129) | 18–24 (N = 6332) | 25–34 (N = 14,797) | 35–45 (N = 13,096) | 46–54 (N = 4304) | 55+ (N = 600) | |||||||
| Age | 34.22 (9.18) | 21.69 (1.85) | 29.63 (2.84) | 39.43 (3.10) | 49.10 (2.38) | 59.34 (4.94) | ||||||
| Vaccine* | ||||||||||||
| Pfizer | 21,620 | 55.3% | 3646 | 57.6% | 8246 | 55.7% | 7135 | 54.5% | 2287 | 53.1% | 306 | 51.0% |
| Moderna | 13,001 | 33.2% | 1916 | 30.3% | 4898 | 33.1% | 4521 | 34.5% | 1448 | 33.6% | 218 | 36.3% |
| Johnson & Johnson | 3469 | 8.9% | 634 | 10.0% | 1260 | 8.5% | 1126 | 8.6% | 406 | 9.4% | 43 | 7.2% |
| Other | 1016 | 2.6% | 133 | 2.1% | 388 | 2.6% | 304 | 2.3% | 159 | 3.7% | 32 | 5.3% |
| Gender | ||||||||||||
| Identifies woman-only |
35,572 | 90.9% | 4535 | 71.6% | 13,449 | 90.9% | 12,751 | 97.4% | 4245 | 98.6% | 592 | 98.7% |
| Gender diverse | 3557 | 9.1% | 1797 | 28.4% | 1348 | 9.1% | 345 | 2.6% | 59 | 1.4% | <10 | – |
| Race | ||||||||||||
| Identifies white-only |
32,983 | 84.3% | 4978 | 78.6% | 12,336 | 83.4% | 11,393 | 87.0% | 3743 | 87.0% | 533 | 88.8% |
| Racially diverse | 6146 | 15.7% | 1354 | 21.4% | 2461 | 16.6% | 1703 | 13.0% | 561 | 13.0% | 67 | 11.2% |
| Ethnicity | ||||||||||||
| Non-Hispanic/ Latinx |
31,134 | 79.6% | 4896 | 77.3% | 11,791 | 79.7% | 10,597 | 80.9% | 3409 | 79.2% | 441 | 73.5% |
| Hispanic/Latinx or other |
7995 | 20.4% | 1436 | 22.7% | 3006 | 20.3% | 2499 | 19.1% | 895 | 20.8% | 159 | 26.5% |
| IUDs | ||||||||||||
| Hormonal | 3694 | 9.4% | 540 | 8.5% | 1725 | 11.7% | 1141 | 8.7% | 274 | 6.4% | 14 | 2.3% |
| Copper/ nonhormonal |
1533 | 3.9% | 157 | 2.5% | 722 | 4.9% | 537 | 4.1% | 112 | 2.6% | <10 | 0.8% |
| Unknown | 47 | 0.1% | <10 | 0.1% | 17 | 0.1% | 16 | 0.1% | <10 | 0.1% | <10 | 0.3% |
| Hormonal treatments | ||||||||||||
| Hormonal contraceptive |
7438 | 19.0% | 1980 | 31.3% | 3588 | 24.2% | 1583 | 12.1% | 277 | 6.4% | 10 | 1.7% |
| Other hormonal treatments |
2980 | 7.6% | 377 | 6.0% | 867 | 5.9% | 1082 | 8.3% | 518 | 12.0% | 136 | 22.7% |
| Cycle regularity | ||||||||||||
| Regular | 28,811 | 73.6% | 4418 | 69.8% | 11,513 | 77.8% | 11,167 | 85.3% | 2662 | 61.8% | 51 | 8.5% |
| Irregular | 4768 | 12.2% | 1206 | 19.0% | 1903 | 12.9% | 989 | 7.6% | 632 | 14.7% | 38 | 6.3% |
| Nonmenstruating | 4525 | 11.6% | 707 | 11.2% | 1377 | 9.3% | 931 | 7.1% | 1003 | 23.3% | 507 | 84.5% |
| Medical history | ||||||||||||
| Past pregnancy | 16,859 | 43.1% | 167 | 2.6% | 3980 | 26.9% | 8841 | 67.5% | 3403 | 79.1% | 468 | 78.0% |
| Parity | 14,579 | 37.3% | 66 | 1.0% | 3049 | 20.6% | 7939 | 60.6% | 3099 | 72.0% | 426 | 71.0% |
| Reproductive conditions |
||||||||||||
| Menorrhagia or heavy bleeding |
6864 | 17.5% | 876 | 13.8% | 2123 | 14.3% | 2529 | 19.3% | 1119 | 26.0% | 217 | 36.2% |
| Endometriosis | 1735 | 4.4% | 142 | 2.2% | 536 | 3.6% | 749 | 5.7% | 266 | 6.2% | 42 | 7.0% |
| PCOS | 3238 | 8.3% | 391 | 6.2% | 1325 | 9.0% | 1194 | 9.1% | 293 | 6.8% | 35 | 5.8% |
| Fibroids | 2449 | 6.3% | 32 | 0.5% | 339 | 2.3% | 1151 | 8.8% | 774 | 18.0% | 153 | 25.5% |
| Adenomyosis | 277 | 0.7% | 11 | 0.2% | 57 | 0.4% | 136 | 1.0% | 64 | 1.5% | <10 | – |
| Other | 2612 | 6.7% | 351 | 5.5% | 956 | 6.5% | 963 | 7.4% | 292 | 6.8% | 50 | 8.3% |